March 12, 2020

Breath Analysis Shows Promise in Diagnosing Gastrointestinal Graft-Versus-Host Disease

A faster, noninvasive way to detect disease

650×450-Dweik

Gastrointestinal graft-versus-host disease (GI GVHD) in patients who have undergone allogeneic hematopoietic cell transplantation (HCT) may someday be diagnosed using a fast, noninvasive test, reports a study conducted at Cleveland Clinic.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

GI GVHD is a common complication of HCT, affecting 30-60% of HCT patients, and a significant cause of morbidity and mortality. Currently, it is diagnosed by clinical examination confirmed by endoscopy with biopsy, an invasive, time-consuming procedure that “can be challenging in patients with low blood counts,” says Betty K. Hamilton, MD, of the Blood and Marrow Transplant Program at the Department of Hematology and Medical Oncology at Cleveland Clinic.

With a need to quickly identify high-risk disease, Dr. Hamilton and colleagues considered another diagnostic method: identification of volatile organic compounds (VOCs) using breath analysis. This technique has shown high accuracy in detecting inflammatory bowel disease (IBD) and efficacy in diagnosing other diseases, such as end-stage renal disease and lung cancer. Raed Dweik, MD, Chairman of Cleveland Clinic’s Respiratory Institute, has spearheaded research on VOCs as a biomarker for 20 years. “The advantage of breath testing is that it is non-invasive and non-intrusive. It does not have a dose limitation like x-rays, an amount limitation like blood tests, or a timing limitation like urine tests. So breath testing can be performed repeatedly as needed,” says Dr. Dweik.

Data have demonstrated an important role of the intestinal microbiome in GI GVHD, with changes in patients who develop GVHD compared to those who do not. It is known that microorganisms can produce volatile metabolites, and thus it is hypothesized that abnormalities in the activity and composition of the intestinal microbiota in disease states may alter the organic compounds produced and expelled in breath.

Investigating VOCs

The study, published in Blood Advances, compared VOCs in 29 patients with and without GI GVHD at day 100 following HCT and 10 healthy controls. The 19 GI GVHD patients had clinically significant GVHD (grade 2-4), with persistent nausea/vomiting or anorexia and/or at least 1 L of diarrhea per day. Using the breath analysis test for VOCs developed by Dr. Dweik’s laboratory, the patients’ exhaled breath samples were analyzed for 22 VOCs using canonical discriminant analysis (CDA). VOCs were analyzed using a logarithmic (log) transformation of each VOC to account for outliers.

Advertisement

VOCs associated with GVHD

The CDA identified five VOCs that differentiated between patients with and without GI GVHD: 2-propanol, acetaldehyde, dimethyl sulfide, isoprene and 1-decene. The model correctly classified 89% and 90% of patients with and without GI GVHD, respectively. Researchers also assessed the correlation between VOCs and GVHD severity. No VOC concentrations were found to have a significant association with GVHD grade.

The study also analyzed the association of VOCs with day 28 response. Of 19 patients, 10 patients achieved complete response (CR), three patients had a partial response (PR), and six had no response. Two VOCs (pentane and ammonia) distinguished patients with CR and less than CR. This model correctly classified 90% of patients with CR and 78% of patients with less than CR. One VOC (acetone) distinguished patients with any response and no response. Patients with higher levels of acetone were less likely to have a response.

A limitation of the study is that half of the GI GVHD patients were exposed to broad-spectrum antibiotics at the time of breath sampling. The 10 patients without GI GVHD did not have an indication for broad-spectrum antibiotics at the time of sampling, although half had recent exposure within the 100-day time period.

“Although a small pilot study, it demonstrated that breath analysis in a transplant and GI GVHD population is feasible and identified a possible “breath signature” that can distinguish GI GVHD and no GVHD. This method may also be able to distinguish between those who had a response to first-line therapy and those who did not. It is exciting that breath analysis could be a possible standard diagnostic method that could replace an invasive procedure in an already sick population,” says Dr. Hamilton.

Advertisement

“Breath analysis for GI GVHD needs a bit more research to confirm the findings and to standardize sample collections and testing. Also, the current equipment is primarily used in a research setting and more work needs to be done to get it to the clinic,” says Dr. Dweik.

Follow-up study in progress

The researchers have begun a larger follow-up study that is collecting breath samples from patients before transplant and at day 30 and day 100 following transplant. The samples will be compared with the microbiome. “The hypothesis is that breath analysis and VOCs correlate with the microbiome; thus there can be many implications in following diseases, such as GVHD and even the primary malignancy, throughout the transplant,” says Dr. Hamilton.

Related Articles

Image of lungs
February 28, 2024
New Cleveland Clinic-Led Research Highlights Novel Disease Monitoring Technique in Heart Failure

Volatile organic compounds have potential in heart failure diagnostics

24-PUL-4507382-CQD-Portopulmonary-Hypertension-Hero-967×544
January 26, 2024
Portopulmonary Hypertension: A Focused Review for the Internist

Insights for diagnosing, assessing and treating

opioids
December 6, 2023
Can Kappa and Alpha-2 Agonist Agents Treat Opioid-Induced Ventilatory Depression Risk While Preserving Analgesic Effects?

Two NIH grants are looking at developing new antidotes against fentanyl overdose

Lab research
November 22, 2023
Unravelling the Mysteries of Sepsis and Septic Shock

Exploring the responses to medications and other supportive therapies

spirometry
August 7, 2023
A Tool to Help in Transition to “Race-Neutral” PFT Interpretation

A set of graphs helps quantify the expected changes in forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio with the new race-neutral equation

Dyspnea
June 2, 2023
Persistent Dyspnea after COVID-19 Infection: Evaluation and Management

Because of the associated symptoms, a multidisciplinary approach to care is essential

Imaging of ribcage
March 8, 2023
COPD and Skeletal Muscle Mass: Discovering New Possibilities

Patients with COPD are often affected by sarcopenia, but the underlying mechanisms for the development are poorly understood. New research looks into the causes and potential therapies

Lungs
January 19, 2023
Looking at the Impact of the New Lung Transplant Allocation System

Research explores how incorporating long-term benefits will impact the new U.S. lung transplant allocation system

Ad